BioStem’s Skin Substitute Reimbursement Faces 12-Month Review
Event summary
- BioStem Technologies’ VENDAJE® and VENDAJE AC® products have been placed on a 12-month “Status Quo” list by CMS for reimbursement related to diabetic foot ulcers (DFU) and venous leg ulcers (VLU).
- The “Status Quo” designation maintains reimbursement eligibility for 2026, requiring adherence to the “reasonable and necessary” standard.
- Coverage for pressure ulcers, representing 41% of the chronic wound market and the majority of BioStem’s revenue, remains unaffected.
- CMS will reconsider the LCD in early 2027 after reviewing evidence submitted by December 31, 2026.
The big picture
This CMS action highlights the ongoing volatility in Medicare reimbursement for advanced wound care products, a sector increasingly subject to rigorous scrutiny. While the “Status Quo” designation provides temporary relief, it underscores the need for BioStem to proactively engage with regulators and build a robust evidence base to ensure long-term market access. The company's reliance on pressure ulcer treatment for the majority of its revenue also exposes it to potential shifts in reimbursement policy for that indication.
What we're watching
- Reimbursement Risk
- The 12-month status quo period introduces significant reimbursement risk, as MACs will scrutinize claims and CMS will reassess coverage based on new evidence.
- Clinical Data
- BioStem’s ability to generate and present compelling clinical data, particularly regarding DFU superiority, will be critical to securing a move from “Status Quo” to “Covered” status.
- Market Dynamics
- The continued stability of BioStem’s pressure ulcer revenue stream will be key, as any shift in reimbursement for this segment could significantly impact overall financial performance.
Related topics